Epi Biotech Co., Ltd., Incheon 21984, Republic of Korea.
Int J Mol Sci. 2024 Jul 11;25(14):7612. doi: 10.3390/ijms25147612.
Therapeutic needs for hair loss are intended to find small interfering ribonucleic acid (siRNA) therapeutics for breakthrough. Since naked siRNA is restricted to meet a druggable target in clinic,, delivery systems are indispensable to overcome intrinsic and pathophysiological barriers, enhancing targetability and persistency to ensure safety, efficacy, and effectiveness. Diverse carriers repurposed from small molecules to siRNA can be systematically or locally employed in hair loss therapy, followed by the adoption of new compositions associated with structural and environmental modification. The siRNA delivery systems have been extensively studied via conjugation or nanoparticle formulation to improve their fate in vitro and in vivo. In this review, we introduce clinically tunable siRNA delivery systems for hair loss based on design principles, after analyzing clinical trials in hair loss and currently approved siRNA therapeutics. We further discuss a strategic research framework for optimized siRNA delivery in hair loss from the scientific perspective of clinical translation.
治疗脱发的需求旨在寻找小干扰核糖核酸(siRNA)疗法以取得突破。由于裸露的 siRNA 在临床上受到限制,无法满足可成药靶点的要求,因此需要使用递送系统来克服内在和病理生理学障碍,提高靶向性和持久性,以确保安全性、疗效和有效性。可以从小分子到 siRNA 的各种载体被系统地或局部用于脱发治疗,然后采用与结构和环境修饰相关的新成分。通过连接或纳米颗粒制剂对 siRNA 递送系统进行了广泛研究,以改善其在体外和体内的命运。在这篇综述中,我们根据设计原则,在分析脱发的临床试验和目前批准的 siRNA 疗法的基础上,介绍了针对脱发的临床可调 siRNA 递送系统。我们还从临床转化的科学角度进一步讨论了优化脱发中 siRNA 递送的战略研究框架。